Personalized de‑intensification of therapy for NLP Hodgkin lymphoma
Official title: Investigating personalized approaches to de-intensify therapy for nodular lymphocyte-predominant Hodgkin lymphoma
Funded at Stanford University · NIH-11355615 · Data updated 2026-11-12
A clinician-scientist at Stanford is developing a patient-centered program to tailor and reduce therapy for nodular lymphocyte-predominant Hodgkin lymphoma using tumor and blood samples.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $284,784 |
| NIH project number | 5K08CA266824-03 |
| Project ID | NIH-11355615 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with nodular lymphocyte-predominant Hodgkin lymphoma or those who recur after standard therapy, under careful clinical supervision.
✕Less likely to help
Patients without NLPHL or those not suitable for therapy de-intensification may not benefit.
What this research studies
This grant supports Dr. Michael Binkley’s career development to build a translational research program that uses patient tumor and blood samples to find genomic and microenvironment factors that predict outcomes. The plan combines clinical care with statistics, genomics, and cancer biology to design kinder, personalized treatment strategies. He will receive formal coursework, mentorship, and hands-on experience in biostatistics, predictive modeling, and prospective clinical protocol design. The effort focuses on NLPHL, a rare lymphoma, with the goal of translating biomarker insights into optimized therapy for patients.
Why it matters
Potential benefit: If successful, patients with NLPHL could receive tailored, potentially less toxic treatments based on their tumor biology.
How similar studies have gone: Prior studies have identified biomarkers that predict outcomes in some lymphomas, suggesting a biomarker-guided approach is promising though NLPHL-specific data are limited.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Binkley, Michael S — Stanford University
- Study coordinator: Binkley, Michael S
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Trajectories of Neurotoxicity in young Hodgkin lymphoma patients
Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Combining international Hodgkin lymphoma data to understand long-term treatment effects
This project brings together trial and registry data to learn how treatments affect long-term health in adults with Hodgkin lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.